ARROWHEAD PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $8.21B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 24, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $75.25M | $-1.36 | – |
| Q2 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $73.74M | $-0.93 | – |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 5, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Sep 30, 2025 | Nov 25, 2025 | During market hours | – | – | – |
| Q3 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $27.77M | $-1.26 | – |
| Q2 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 10, 2025 | During market hours | $2.50M | $-1.39 | – |
| Q4 FY2024 Ended Sep 30, 2024 | Nov 26, 2024 | During market hours | – | – | – |
| Q3 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Dec 31, 2023 | Feb 6, 2024 | During market hours | – | – | – |
Press releases
Announcements Arrowhead Pharmaceuticals filed with the SEC
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and
Material agreement · Other events · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Obesity KOL Webinar ARO-INHBE and ARO-ALK7 Interim Phase 1/2a Clinical Data January 06, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
Results of operations · EX-99.1 to Form 8-K
REDEMPLO® (plozasiran) FDA Approval Conference Call November 18, 2025
Other events · EX-99.2 to Form 8-K
Exhibit 1 Case 2:25-cv-08609 Document 1-1 Filed 09/11/25 Page 1 of 48 Page ID #:18
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
Other events · EX-99.2 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Agreement terminated · Other events · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Regulation FD disclosure · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
Regulation FD disclosure · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
Results of operations · EX-99.1 to Form 8-K